Skip to main content
OpenTrials
Completed

NCT Number: NCT00689117

A Clinical Study to Evaluate the Safety and Effectiveness of an Investigational Product Called CT Gel

The purpose of this study is to demonstrate the safety and effectiveness of CT Gel in subjects with acne vulgaris. The hypothesis is that CT Gel is superior to Clindamycin Gel, Tretinoin Gel and Vehicle Gel for the treatment of acne vulgaris.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Acne Vulgaris Acne Acneiform Eruptions Sebaceous Gland Diseases Skin Diseases Skin and Connective Tissue Diseases

Age range

12 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Dermatology And Skin Centre, Belize City, Belize

Loading trial locations.

About this study

CT Gel is a fixed-combination product that addresses the multifactorial factors of acne vulgaris pathogenesis. Based on numerous nonclinical pharmacology studies of each active ingredient, it is expected that this new product will have three biological actions: 1) comedolytic, 2) antimicrobial, and 3) anti-inflammatory.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female 12 years of age or older in good general health
  • Investigator's Static Global Assessment (ISGA) score of 2 or greater at Baseline

Exclusion criteria

  • Any nodulo-cystic lesions at Baseline
  • Pregnancy or breast feeding
  • History or presence of regional enteritis or inflammatory bowel disease or similar symptoms.
  • Treatment with estrogens, including oral, implanted and topical contraceptives, androgens, or anti-androgenic agents for 12 weeks or less prior to study start.
  • Use of topical anti-acne medications within the past 2 weeks.
  • Use of topical or systemic antibiotics on the face within the past 2 weeks.
  • Use of topical or systemic corticosteroids within the past 2 weeks.
  • Use of systemic retinoids within the past 3 months.
  • Use of astringents, toners and skin cleansers for less than 2 weeks prior to the start of the study.
  • Concomitant use of facial product containing glycolic or other acids, masks, washes or soaps containing benzoyl peroxide or salicylic acid, non mild cleansers or moisturizers containing retinol, salicylic or α- or β-hydroxy acids.
  • Concomitant use of mega-doses of certain vitamins, such as vitamin D (>2000IU QD) vitamin B12, haloperidol, halogens such as iodide and bromide, lithium, hydantoin and phenobarbital.
  • Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 2 weeks or during the study.
  • Concomitant use of tanning booths or sunbathing.
  • Known hypersensitivity or previous allergic reaction to any of the active components, lincomycin, retinoids or excipients of the study product
  • A significant medical history of or are currently immunocompromised
  • Current drug or alcohol abuse. (Drug screening not required.)
  • Use of any investigational therapy within 4 weeks of enrollment.
  • Any other condition which, in the judgment of the investigator, would put the subject at unacceptable risk for participation in the study.

Treatment and study plan

CT Gel

Drug

Topical gel consisting of clindamycin 1% and tretinoin 0.025%, applied once daily in the evening for 12 weeks

Clindamycin Gel (clindamycin )

Drug

Clindamycin 1% gel applied topically once daily in the evening for 12 weeks

Tretinoin Gel (tretinoin)

Drug

Tretinoin 0.025% gel applied topically once daily in the evening for 12 weeks

Vehicle gel

Drug

Topical gel without clindamycin or tretinoin applied topically once daily in the evening for 12 weeks

Primary outcomes

  1. Absolute Change From Baseline in Lesion Counts (Total, Inflammatory, and Non-inflammatory) at Week 12 (End of Study)

    Time frame: Baseline, Week 12

    Acne lesion counts (inflammatory [papules, pustules, nodules], non-inflammatory [open and closed comedones], and total) were performed on the face of participants. Change from baseline is defined as Week 12 values minus Baseline values. The total lesion count is the sum of the inflammatory and non-inflammatory lesion counts.

  2. The Percentage of Participants Who Had a Minimum 2-grade Improvement in the Investigator's Static Global Assessment (ISGA) Score From Baseline to Week 12

    Time frame: Baseline, Week 12

    The ISGA is a static ("snap-shot") evaluation of acne severity performed by an investigator/assessor at every visit. The ISGA score is measured on a 6-point ordinal scale, where 0=Clear and 5=Very Severe. Change is calculated as the Week 12 value minus the Baseline value.

Secondary outcomes

  1. Percent Change From Baseline in Lesion Counts (Inflammatory, Non-inflammatory, and Total) at Week 12

    Time frame: Baseline, Week 12

    Acne lesion counts (inflammatory [papules, pustules, nodules], non-inflammatory [open and closed comedones], and total) were performed on the face of participants. Change from baseline is defined as Week 12 values minus Baseline values. The total lesion count is the sum of the inflammatory and non-inflammatory lesion counts.

  2. The Percentage of Participants With a Subjects Global Assessment Score of 0 or 1 at Week 12

    Time frame: Week 12

    The SGA score is a global evaluation of acne severity performed by participants at all visits and measured on a 5-point ordinal scale, where 0=My face is basically free of acne and 5=My face has blackheads and/or whiteheads. A score of 1=My face has several blackheads and/or whiteheads and small pimples, but there are no tender deep-seated bumps or cysts.

  3. The Percentage of Participants Who Had ISGA Scores of 0 or 1 at Week 12

    Time frame: Week 12

    The ISGA is a static ("snap-shot") evaluation of acne severity performed by an investigator/assessor at every visit. The ISGA score is measured on a 6-point ordinal scale, where 0=Clear and 5=Very Severe. A score of 1=Skin Almost Clear: rare non-inflammatory lesions present, with rare non-inflamed papules (papules must be resolving and may be hyper-pigmented, though not pink-red) requiring no futher treatment in the Investigator's opinion.

Sponsors and collaborators

Lead sponsor

Stiefel, a GSK Company

Industry

Collaborators

  • GlaxoSmithKline

Registry information

Official study title

A Phase 3 Multicenter, Randomized, Double-Blind, Active And Vehicle-Controlled Study Of The Safety And Efficacy Of CT Gel in Subjects With Acne Vulgaris

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Jun 3, 2008
Registry last updated
May 30, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.